Clinical trial

Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

NCT03506997

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2018-11-27

PhasePHASE2

Study timeline

Study start (actual)2018-11-27Date precision: day

Registry last updated2020-07-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Castration-resistant Prostate Cancerunresolved

Interventions

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Sponsors & collaborators

Institute of Cancer Research, United Kingdomlead sponsor

Merck Sharp & Dohme LLCcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03506997 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.